Talk to your prescribing provider or pharmacist about switching to 5 mg/ml as you approach the higher dose tiers
Tirzepatide is an injectable medication that mimics two key hormones, GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide), to regulate blood sugar and appetite
The physiology is poorly understood, but may relate to changes in hypothalamic thermoregulation associated with fluctuations in estrogen levels
In clinical trials with primary endpoints ranging from 26 to 52 weeks, weight change was a secondary endpoint
"But this mass compounding its quite unbelievable that it has gotten to this point." He added that Novo has filed multiple lawsuits against compounders, arguing that the launch of a compounded pill version crossed a line
Most of the gray market buyers Reuters interviewed had told their medical providers they were taking GLP-1 medicines but not where or how they bought them